title: [Room temperature phosphorescence of amorphous aggregates and amyloid fibrils resulting from protein misfolding].
abstract: Using actin, alpha-lactalbumin and insulin as examples, it was shown that the formation of amorphous aggregates of proteins and amyloid fibrils leads to an increase in the rigidity of tryprophan and tyrosine residues micro-environment and, consequently, to the appearance of tryptophan (tyrosine) room temperature phosphorescence (RTP). RTP was used for examining a slow intramolecular mobility of native (G-, F-form) and inactivated (I) rabbit skeletal muscle actin during the process of GdnHCl induced protein unfolding. This method made it possible to confirm that an essentially unfolded intermediate precedes the formation of inactivated actin. It has been found that the kinetic intermediate generated at the early stage of protein denaturation has no tryptophan RTP, suggesting a high lability of its structure. Symbate changes of integral intensity (relative quantum yield) and the mean lifetime of RTP during the U*-->I transition suggest a gradual increase of the number of monomers incorporated in the associate (U*-->11...-->In...-->I15), which is accompanied by an increase of protein structural rigidity. The rate of inactivated actin formation (I-->I15) is shown to increase with the increase of protein concentration. It is shown that, no matter what method of inactivation was employed (1--2 M GdnHCl or 3.0-3.5 M urea, Ca2+ removal, incubation at 70 degrees C, refolding from completely unfolded state by dialysis from 8 M urea or 6 M GdnHCl), actin transition to the inactivated state is accompanied by a significant increase in both integral intensity and the mean lifetime of RTP, suggesting the rigid structure of inactivated actin. It is shown that the lifetime of inactivated actin RTP does not depend on GdnHCl concentration within the limits from 0 to 4 M. On using insulin and alpha-lactalbumin as examples, it is shown that RTP can be used in studies of fibrillogenesis and properties of amyloid fibrils.
authors.forename: V M
authors.initials: VM
authors.lastname: Mazhul'
authors.forename: E M
authors.initials: EM
authors.lastname: Zaĭtseva
authors.forename: M M
authors.initials: MM
authors.lastname: Shavlovskiĭ
authors.forename: O I
authors.initials: OI
authors.lastname: Povarova
authors.forename: I M
authors.initials: IM
authors.lastname: Kuznetsova
authors.forename: K K
authors.initials: KK
authors.lastname: Turoverov
mesh_terms: D000199:Actins / Q000737:chemistry / Q000378:metabolism*; D000682:Amyloid / Q000378:metabolism; D000686:Amyloidosis / Q000209:etiology; D000818:Animals; D002417:Cattle; D019791:Guanidine / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism; D007700:Kinetics; D007768:Lactalbumin / Q000737:chemistry / Q000378:metabolism*; D049449:Luminescence; D008163:Luminescent Measurements; D018482:Muscle, Skeletal / Q000737:chemistry; D017096:Prion Diseases / Q000209:etiology; D011489:Protein Denaturation; D017510:Protein Folding; D011817:Rabbits; D013696:Temperature; D014364:Tryptophan
chemical_list: D000199:Actins; D000682:Amyloid; D007328:Insulin; D014364:Tryptophan; D007768:Lactalbumin; D019791:Guanidine